Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
$2.30
$0.00(0.00%)
At close: 4:00 PM EST
$2.30
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $3.48
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$79.22M
Enterprise Value$37.24M
Total Cash (Recent Filing)$1.86M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Mar 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding34,443,560
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio-2.27
Price to Book (P/B)37.05
Price to Sales (P/S)0.00
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.66K
Enterprise Value/Ebitda-1.80
Forecast
1Y Price Target
$5.83Price Target Upside153.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe initial target market includes patients with elevated cardiac risk in concierge practices, representing a substantial revenue opportunity for Heartbeam.
Regulatory ApprovalHeartbeam received FDA clearance for its 12-lead ECG synthesis software, marking it as the first at-home option to provide clinical grade ECG output with 24/7 cardiologist review.
Strategic PartnershipsHeartbeam has a nationwide reader service through a partnership with HeartNexus, ensuring 24/7 cardiology support and timely ECG assessments for patients.
Bears Say
Financial StabilityCash on hand combined with interim financing alternatives are sufficient to fund operations for the next several weeks, with a more significant funding event likely following the upcoming 510(k) clearance later this year.
Potential RisksPotential risks to the company's price target include regulatory setbacks, delays in commercialization, reimbursement headwinds, and unforeseen competitive threats.
Regulatory ChallengesIn November 2025, the company received a Not Substantially Equivalent (NSE) decision from the FDA for the 510(k) application.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $3.48 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $79.22M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is Mar 19, 2026 which is in 93 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Nov 13, 2025. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.129 by -$0.021.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.14.
How many shares outstanding does HeartBeam have?
HeartBeam has 34,443,560 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.129. Following the earnings report the stock price went down -0.637%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.83 (153.48% Upside)
$5.83 (153.48% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-792.01%
Trailing 12-Months
Asset Growth
-40.93%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc. (BEAT) is a healthcare technology company focused on developing advanced solutions for cardiovascular disease detection and management. Operating in the medical device sector, the company specializes in creating innovative, portable, and easy-to-use heart monitoring products aimed at improving patient outcomes and reducing healthcare costs. Its core offerings include a proprietary system designed to enable users to take a 12-lead electrocardiogram (ECG) outside of a medical setting and transmit the data to healthcare providers.
BEAT Company Deck
BEAT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards FDA clearance and commercial readiness, including strategic partnerships and successful clinical trials. However, the tight cash position and dependence on the FDA clearance present notable challenges.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$5.83
▲(153.48% Upside)
Technical Analysis
Ownership Overview
14.86% Insiders
3.88% Mutual Funds
2.16% Other Institutional Investors
76.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---